Identification

Name
Eletriptan
Accession Number
DB00216
Description

Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 382.519
Monoisotopic: 382.171498776
Chemical Formula
C22H26N2O2S
Synonyms
  • Eletriptán
  • Eletriptan
  • élétriptan
  • Eletriptanum
External IDs
  • UK-116,044
  • UK-116,044-04 FREE BASE
  • UK-116044
  • UK-116044-04 FREE BASE

Pharmacology

Indication

For the acute treatment of migraine with or without aura in adults.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Eletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.

Mechanism of action

Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. In contrast, eletriptan displays insignificant pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. While the full mechanism of action of 5-HT receptor agonists in relieving migrains is not fully elucidated, it is proposed that the activation of 5-HT1 receptors located on intracranial blood vessels leads to vasoconstriction that correlates with the relief of migraine headaches. It is also proposed that the activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system leads to the inhibition of release of pro-inflammatory neuropeptides.

TargetActionsOrganism
A5-hydroxytryptamine receptor 1D
agonist
Humans
A5-hydroxytryptamine receptor 1B
agonist
Humans
A5-hydroxytryptamine receptor 1F
agonist
Humans
U5-hydroxytryptamine receptor 1A
agonist
Humans
Absorption

Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.

Volume of distribution
  • 138 L
Protein binding

Plasma protein binding is moderate and approximately 85%.

Metabolism

In vitro studies indicate that eletriptan is primarily metabolized by cytochrome P-450 enzyme CYP3A4. The N-demethylated metabolite of eletriptan is the only known active metabolite.

Hover over products below to view reaction partners

Route of elimination
Not Available
Half-life

The terminal elimination half-life of eletriptan is approximately 4 hours.

Clearance
  • Renal cl=3.9 L/h
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3---(C;T) / (T;T)T AlleleEffect Directly StudiedPatients with this genotype have an increased likelihood of responding to elitriptan when treating (condition: cluster headache).Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Eletriptan can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Eletriptan can be increased when combined with Abatacept.
AbirateroneThe metabolism of Eletriptan can be decreased when combined with Abiraterone.
AcebutololThe metabolism of Eletriptan can be decreased when combined with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Eletriptan is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when Eletriptan is combined with Acemetacin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Eletriptan.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Eletriptan.
AcetazolamideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Acetazolamide.
AcetohexamideThe metabolism of Acetohexamide can be decreased when combined with Eletriptan.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with or without food. High-fat meals increase exposure, but not to a clinically relevant extent.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Eletriptan hydrobromideM41W832TA3177834-92-3UTINOWOSWSPFLJ-FSRHSHDFSA-N
Eletriptan hydrobromide monohydrate4139X692FA273211-28-2BORDVONYOHPTGR-JQDLGSOUSA-N
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EletriptanTablet40 mgOralPro Doc Limitee2019-07-31Not applicableCanada flag
EletriptanTablet20 mgOralPro Doc Limitee2019-07-31Not applicableCanada flag
RelpaxTablet20 mgOralUpjohn Canada Ulc2004-10-13Not applicableCanada flag
RelpaxTablet, film coated40 mg/1OralU.S. Pharmaceuticals2002-12-26Not applicableUS flag
RelpaxTablet, film coated40 mg/1OralRebel Distributors2002-12-26Not applicableUS flag
RelpaxTablet, film coated40 mg/1OralRoerig2002-12-26Not applicableUS flag00049 2340 05 nlmimage10 381c9c54
RelpaxTablet, film coated40 mg/1OralStat Rx USA2002-12-26Not applicableUS flag
RelpaxTablet40 mgOralUpjohn Canada Ulc2004-10-13Not applicableCanada flag
RelpaxTablet, film coated20 mg/1OralRoerig2002-12-26Not applicableUS flag00049 2330 45 nlmimage10 3c1c9e04
RelpaxTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2007-11-19Not applicableUS flag54868 552820180907 15195 nxabtg
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-eletriptanTabletOralApotex Corporation2013-09-12Not applicableCanada flag
Apo-eletriptanTabletOralApotex Corporation2013-09-12Not applicableCanada flag
Auro-eletriptanTabletOralAuro Pharma Inc2019-02-01Not applicableCanada flag
Auro-eletriptanTabletOralAuro Pharma Inc2019-02-01Not applicableCanada flag
EletriptanTablet, film coated40 mg/1OralGreenstone LLC2017-07-24Not applicableUS flag
EletriptanTablet, film coated20 mg/1OralGreenstone LLC2017-07-24Not applicableUS flag
Eletriptan HydrobromideTablet, film coated20 mg/1OralAurobindo Pharma Limited2019-01-15Not applicableUS flag
Eletriptan HydrobromideTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2017-08-15Not applicableUS flag
Eletriptan hydrobromideTablet, film coated20 mg/1OralCadila Healthcare Limited2017-07-12Not applicableUS flag
Eletriptan HydrobromideTablet, film coated40 mg/1OralAjanta Pharma Limited2017-08-29Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
N02CC06 — Eletriptan
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
3-alkylindoles
Alternative Parents
Benzenesulfonyl compounds / Aralkylamines / Substituted pyrroles / N-alkylpyrrolidines / Sulfones / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
3-alkylindole / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenesulfonyl group / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfone, indoles, N-alkylpyrrolidine (CHEBI:50922)

Chemical Identifiers

UNII
22QOO9B8KI
CAS number
143322-58-1
InChI Key
PWVXXGRKLHYWKM-LJQANCHMSA-N
InChI
InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
IUPAC Name
5-[2-(benzenesulfonyl)ethyl]-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole
SMILES
CN1CCC[[email protected]@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2

References

Synthesis Reference

Ronald Ogilvie, "Process for the preparation of eletriptan." U.S. Patent US20050059828, issued March 17, 2005.

US20050059828
General References
Not Available
Human Metabolome Database
HMDB0014361
KEGG Drug
D07887
PubChem Compound
77993
PubChem Substance
46506380
ChemSpider
70379
BindingDB
50103594
RxNav
231049
ChEBI
50922
ChEMBL
CHEMBL1510
ZINC
ZINC000003823475
Therapeutic Targets Database
DAP000008
PharmGKB
PA134687947
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Eletriptan
AHFS Codes
  • 28:32.28 — Selective Serotonin Agonists
FDA label
Download (148 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedOtherWorkplace Migraine Treatment1
4CompletedPreventionMigraine1
4CompletedTreatmentMigraine3
3CompletedTreatmentMigraine Disorders1
3CompletedTreatmentMigraine Headache, With or Without Aura4
3CompletedTreatmentMigraine With Aura / Migraine Without Aura1
2CompletedTreatmentMigraine Disorders1
1CompletedBasic ScienceHealthy Volunteers2
Not AvailableCompletedNot AvailableMigraine Disorders3
Not AvailableCompletedTreatmentAcute Migraine / Headache Disorders / Migraine1

Pharmacoeconomics

Manufacturers
  • Pfizer ireland pharmaceuticals
Packagers
  • Chunghwa Chemical Synthesis and Biotech Co. Ltd.
  • Pfizer Inc.
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • US Pharmaceutical Group
Dosage Forms
FormRouteStrength
Tablet, coatedOral20 MG
Tablet, film coatedOral20 MG
Tablet, film coatedOral40 MG
Tablet, film coatedOral20 mg/1
TabletOral
TabletOral20 MG
TabletOral40 MG
Tablet, coatedOral80 MG
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral
Tablet, coatedOral40 mg
Prices
Unit descriptionCostUnit
Relpax 6 20 mg tablet Box156.05USD box
Relpax 6 40 mg tablet Box156.05USD box
Relpax 20 mg tablet25.01USD tablet
Relpax 40 mg tablet25.01USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
CA2352392No2006-01-242019-11-01Canada flag
CA2198599No2000-06-062015-05-17Canada flag
US5545644No1996-08-132016-12-26US flag
US6110940No2000-08-292017-08-29US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityReadily soluble as hydrobromide formulationNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00118 mg/mLALOGPS
logP3.84ALOGPS
logP3.77ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)16.56ChemAxon
pKa (Strongest Basic)8.37ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.17 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.94 m3·mol-1ChemAxon
Polarizability42.99 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9872
Blood Brain Barrier+0.9774
Caco-2 permeable-0.628
P-glycoprotein substrateSubstrate0.6308
P-glycoprotein inhibitor INon-inhibitor0.8046
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.7
CYP450 2C9 substrateNon-substrate0.6591
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.643
CYP450 1A2 substrateNon-inhibitor0.7021
CYP450 2C9 inhibitorNon-inhibitor0.8103
CYP450 2D6 inhibitorNon-inhibitor0.7615
CYP450 2C19 inhibitorNon-inhibitor0.7519
CYP450 3A4 inhibitorNon-inhibitor0.6355
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6986
Ames testNon AMES toxic0.5945
CarcinogenicityNon-carcinogens0.8556
BiodegradationNot ready biodegradable0.9883
Rat acute toxicity2.5492 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6436
hERG inhibition (predictor II)Inhibitor0.7581
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663]
  3. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [PubMed:15821444]
  4. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839]
  5. Strijbos PJ, Parsons AA, Fugelli A: Eletriptan Pfizer. Curr Opin Investig Drugs. 2002 Sep;3(9):1359-68. [PubMed:12498013]
  6. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663]
  2. van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR: Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73. [PubMed:11050304]
  3. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L: Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000 Nov;12(11):3991-4002. [PubMed:11069595]
  4. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839]
  5. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS: Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res. 2002 Oct 25;953(1-2):181-8. [PubMed:12384251]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1F
Uniprot ID
P30939
Uniprot Name
5-hydroxytryptamine receptor 1F
Molecular Weight
41708.505 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663]
  2. Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR: Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. [PubMed:11834243]
  3. Jahnichen S, Radtke OA, Pertz HH: Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):54-63. Epub 2004 Jun 8. [PubMed:15185063]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9. [PubMed:12814962]
  3. Eletriptan FDA label [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9. [PubMed:12814962]
  2. Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S: Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects. Drug Des Devel Ther. 2018 Feb 19;12:331-337. doi: 10.2147/DDDT.S149119. eCollection 2018. [PubMed:29497279]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Capi M, Curto M, Lionetto L, de Andres F, Gentile G, Negro A, Martelletti P: Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23. doi: 10.1177/1756285616650619. Epub 2016 Jun 3. [PubMed:27582896]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Pichard-Garcia L, Hyland R, Baulieu J, Fabre JM, Milton A, Maurel P: Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos. 2000 Jan;28(1):51-7. [PubMed:10611140]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9. [PubMed:12814962]
  2. Tepper SJ: Safety and rational use of the triptans. Med Clin North Am. 2001 Jul;85(4):959-70. [PubMed:11480267]

Drug created on June 13, 2005 07:24 / Updated on November 30, 2020 13:38

Logo pink
Combine AI with DrugBank’s data
to build predictive models.
Our clients have developed successful models for drug targets, side effects, toxicity, and drug-drug interactions. Learn More.